5-(carboxymethyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydroisoxazole-5-carboxylic acid | 847675-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(carboxymethyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydroisoxazole-5-carboxylic acid
• 英文别名: 5-carboxymethyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-isoxazole-5-carboxylic acid；5-(carboxymethyl)-3-(3-cyclopentyloxy-4-methoxyphenyl)-4H-1,2-oxazole-5-carboxylic acid
• CAS: 847675-54-1
• 化学式: C₁₈H₂₁NO₇
• 分子量: 363.367
• InChiKey: WJAOVHOFRUDAMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-(carboxymethyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydroisoxazole-5-carboxylic acid 在 sodium tetrahydroborate 、 三氟化硼 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 17.0h， 生成 2-[3-(3-cyclopentyloxy-4-methoxy-phenyl)-5-hydroxymethyl-4,5-dihydro-isoxazol-5-yl]-ethanol
  参考文献：
  名称：

  [EN] INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
  [FR] INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE IV

  摘要：

  公开号：

  WO2005021515A3
• 作为产物：
  描述：

  3-(3-cyclopentyloxy-4-methoxy-phenyl)-5-methoxycarbonylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester 在 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 5-(carboxymethyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydroisoxazole-5-carboxylic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
  [FR] INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE IV

  摘要：

  公开号：

  WO2005021515A3

文献信息

• Isoxazolines and their use as inhibitors of phosphodiesterase type-IV
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1840123A1

  公开（公告）日：2007-10-03

  The present invention relates to isoxazoline derivatives of formula I, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

  本发明涉及公式I的异噁唑啉衍生物，可用作选择性磷酸二酯酶（PDE）IV型抑制剂。特别是，本文披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺病（COPD）、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的治疗，尤其是在人类患者中。本发明还涉及所述化合物的制备方法，以及其药物组合物和作为磷酸二酯酶（PDE）IV型抑制剂的用途。
• Inhibitors of phophodiesterase type-IV
  申请人：Palle P. Venkata

  公开号：US20050075383A1

  公开（公告）日：2005-04-07

  The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

  本发明涉及异噁唑啉衍生物，可用作选择性磷酸二酯酶（PDE）IV型抑制剂。特别是，所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病（COPD）、银屑病、过敏性鼻炎、休克、特应性皮炎、克隆病、成人呼吸窘迫综合症（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的患者，特别是人类。本发明还涉及所披露化合物的制备方法，以及其作为磷酸二酯酶（PDE）IV型抑制剂的药物组合物和用途。
• CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV
  申请人：Palle Venkata P.

  公开号：US20090048247A1

  公开（公告）日：2009-02-19

  The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

  本发明涉及异噁唑啉衍生物，可用作选择性磷酸二酯酶（PDE）IV型抑制剂。特别地，本文所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病（COPD）、银屑病、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合症（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病的患者，特别是人类。本发明还涉及所披露的化合物的制备方法，以及其作为磷酸二酯酶（PDE）IV型抑制剂的药物组合物及其应用。
• Inhibitors of phosphodiesterase type-IV
  申请人：Balachandran Sarala

  公开号：US20080009535A1

  公开（公告）日：2008-01-10

  The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

  本发明涉及异氧嗪衍生物，可用作选择性磷酸二酯酶（PDE）IV型抑制剂。特别地，本文所披露的化合物可用于治疗艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺疾病（COPD）、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合症（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎以及其他炎症性疾病的患者中，尤其是人类。本发明还涉及所披露的化合物的制备过程、以及它们作为磷酸二酯酶（PDE）IV型抑制剂的药物组合物及其使用。
• WO2006/85212
  申请人：——

  公开号：——

  公开（公告）日：——